BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?Zacks Investment Research • 09/19/23
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatmentProactive Investors • 09/18/23
INESSS Recommends Public Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in QuébecGlobeNewsWire • 09/18/23
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/03/23
Wall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a BetZacks Investment Research • 07/20/23
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in TurkeyGlobeNewsWire • 07/19/23
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology CongressGlobeNewsWire • 05/31/23
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of ChileGlobeNewsWire • 05/22/23
BioCryst Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/03/23
BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)GlobeNewsWire • 04/27/23
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from PharmakonGlobeNewsWire • 04/18/23
CADTH Recommends Reimbursement for BioCryst's ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in CanadaGlobeNewsWire • 03/08/23
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)GlobeNewsWire • 02/24/23